Latest news with #immuno-oncology
Yahoo
14-07-2025
- Business
- Yahoo
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
MADISON, Wis., July 14, 2025--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a clinical stage biotech company in Pittsburgh, PA. Most recently, he served as Senior Vice President of Human Immunology at Vir Biotechnology. Prior to that, he served as Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. During his tenure at BMS and Medarex, Dr. Korman contributed to the development of three approved oncology drugs: ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and relatlimab (anti-LAG-3), as well as their combination, pioneering the use of immune checkpoint blockade in cancer therapy. Dr. Korman earned his PhD in Cellular and Developmental Biology from Harvard University and was a Whitehead Fellow at the Whitehead Institute at the Massachusetts Institute of Technology. He also served as a staff scientist at the Institut Pasteur before transitioning to the biotechnology sector. In addition to his new role on Invenra's SAB, Dr. Korman is also the founder of Spice Biotechnologies, a company focused on developing next-generation checkpoint therapeutics. "We are thrilled to welcome Dr. Korman to our Scientific Advisory Board," said Dr. Roland Green, Co-Founder, CEO, and Chairman of Invenra. "His extensive experience in developing transformative immunotherapies aligns perfectly with Invenra's mission to collaborate with and support biotech and pharmaceutical companies of all sizes globally. We look forward to his valuable insights and contributions as we continue to empower our partners to advance innovative therapeutics." Dr. Korman joins SAB members Dr. Paul Sondel and Dr. Jonathan Davis, whose knowledge and guidance have supported Invenra's research and development. Dr. Paul Sondel, MD, PhD, is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin–Madison. With a distinguished career in cancer immunotherapy, Dr. Sondel has led lab, translational, and clinical research within the UW Carbone Cancer Center. His work has significantly advanced the understanding and application of immunotherapeutic strategies, including the development of FDA-approved treatments for high-risk neuroblastoma. Dr. Jonathan Davis, PhD, brings over 20 years of experience in the life sciences industry, focusing on protein and antibody engineering, as well as bispecific and multispecific antibody platform development. Prior to joining the Invenra SAB, Dr. Davis was Vice President of Innovation and Strategy for Invenra where he focused on optimization of the B-Body Platform, the development of antibody libraries, and refinements to screening methodology and throughput. Prior to Invenra, he was a Principal Scientist at Bristol-Myers Squibb, where he contributed to biologic drug design, including the development of a trispecific HIV biotherapeutic. Prior to that, he worked at EMD Serono, where he developed a variety of novel biologic drug platforms. "The collective expertise of Drs. Korman, Sondel, and Davis positions Invenra as a key collaborator and service provider, driving the discovery and development of multispecific antibody-based therapeutics in partnership with biotech and pharmaceutical companies worldwide," added Dr. Green. "Their combined knowledge and experience will be invaluable as we continue to support our partners in bringing novel treatments to patients in need." For more information about Invenra and its Scientific Advisory Board, please visit About Invenra Invenra Inc. is a biotechnology company specializing in next-generation multispecific antibody discovery and development. Its proprietary B-Body® platform enables the rapid generation of highly developable bispecifics and now supports both Rapid Bispecific Discovery Services—delivering lead panels in as little as four months—and B-Body Express™, which quickly produces high-quality bispecifics from partner-provided sequences. Invenra's newly launched T-Body™ platform expands these capabilities for efficient expression, correct chain pairing, and robust assembly of trispecific constructs. Invenra partners globally with pharmaceutical and biotech companies to accelerate therapeutic antibody programs from discovery through preclinical development. View source version on Contacts Invenra Inc.5510 Element Way, Suite 400Madison, WI 53719Phone: 608.441.8319Email: info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-07-2025
- Business
- Yahoo
I-Mab to Present at the BTIG Virtual Biotechnology Conference
ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the 'Company'), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025. Conference details are as follows: BTIG Virtual Biotechnology ConferenceFormat: Fireside Chat and one-on-one meetingsDate: Tuesday, July 29, 2025Time: 10:00 AM ETWebcast Link: Available on the News & Events page of the I-Mab website The webcast of the event will be accessible from News & Events page of the I-Mab website for 90 days. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Investor & Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 pkelleher@ IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is among the . H.C. Wainwright analysts have reiterated their Buy rating on BioXcel Therapeutics, Inc. (NASDAQ:BTAI), while maintaining a price target of $8.00. This confidence stems from the favorable trial developments for the company's BXCL501 treatment. The Data Safety Monitoring Board (DSMB) put forward a second positive recommendation to BioXcel Therapeutics, Inc. (NASDAQ:BTAI), allowing the company to continue its SERENITY At-Home pivotal Phase 3 safety trial without modifications. This suggestion followed a review of unblinded safety data from 178 patients dosed through May 28, 2025. A scientist at a computer station, surrounded by a neural network of artificial intelligence code. As per the research firm, SERENITY readout exhibits low risk as the main outcome is safety-based, and considering the institutional settings, IGALMI has already received approval. While the expanded label is expected to be filed by the end of this year, the firm anticipates that BioXcel Therapeutics, Inc. (NASDAQ:BTAI) will receive a label extension during the second half of 2026. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a Connecticut-based biopharmaceutical company, alongside its subsidiary, OnkosXcel Therapeutics LLC. Founded in 2017, the company employs AI to develop medicines in the areas of neuroscience and immuno-oncology. While we acknowledge the potential of BTAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
11-07-2025
- Business
- Yahoo
BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is among the . H.C. Wainwright analysts have reiterated their Buy rating on BioXcel Therapeutics, Inc. (NASDAQ:BTAI), while maintaining a price target of $8.00. This confidence stems from the favorable trial developments for the company's BXCL501 treatment. The Data Safety Monitoring Board (DSMB) put forward a second positive recommendation to BioXcel Therapeutics, Inc. (NASDAQ:BTAI), allowing the company to continue its SERENITY At-Home pivotal Phase 3 safety trial without modifications. This suggestion followed a review of unblinded safety data from 178 patients dosed through May 28, 2025. A scientist at a computer station, surrounded by a neural network of artificial intelligence code. As per the research firm, SERENITY readout exhibits low risk as the main outcome is safety-based, and considering the institutional settings, IGALMI has already received approval. While the expanded label is expected to be filed by the end of this year, the firm anticipates that BioXcel Therapeutics, Inc. (NASDAQ:BTAI) will receive a label extension during the second half of 2026. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is a Connecticut-based biopharmaceutical company, alongside its subsidiary, OnkosXcel Therapeutics LLC. Founded in 2017, the company employs AI to develop medicines in the areas of neuroscience and immuno-oncology. While we acknowledge the potential of BTAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
09-07-2025
- Business
- Yahoo
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III
Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on two highly anticipated trials for head and neck squamous cell carcinoma/HNSCC. The announcements for these presentations were made earlier in May. Merus presented data from its Phase II study of petosemtamab, which is a bispecific monoclonal antibody targeting epidermal growth factor receptor/EGFR and Leucine-rich repeat containing G-Protein coupled receptor 5/LGR5, in combination with Merck's Keytruda (pembrolizumab) for PDL1+ first-line (1L) HNSCC. A scientist looking through a microscope conducting research in an immuno-oncology lab. Bicara presented Phase I/Ib data for its ficerafusp alfa, a bispecific fusion protein targeting EGFR and transforming growth factor beta (TGF-β), also in combination with Keytruda in the same patient population. Both Merus and Bicara are progressing their assets into Phase III clinical development. However, Bicara's ficerafusp alfa is being advanced with a narrower patient population, specifically excluding those positive for human papillomavirus/HPV. Merus (NASDAQ:MRUS) is a clinical-stage immuno-oncology company that develops antibody therapeutics in the Netherlands. While we acknowledge the potential of MRUS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
